Full-line wholesalers in the EU perform an unrecognized role, United Drug chief says

22 June 2008

Full-line prescription drug wholesaling has an intrinsic value, based on carrying and supplying a full range of medicines that benefits governments, manufacturers and patients alike, according to Liam Fitzgerald, chief executive of United Drug, a provider of services to pharmaceutical retailers and manufacturers and Ireland's largest pharmaceutical wholesaler. He was speaking at the 49th Annual General Meeting of the European Association of Pharmaceutical Full-line Wholesalers (GIRP) in Prague, the Czech Republic.

Mr Fitzgerald warned: "attempts by any stakeholder to cherry pick product ranges or price services without due recognition of the cross-subsidization nature of our service, or to delimit wholesaling to a pure logistics operation, will ultimately do patients a dis-service and will compromise the de facto public service aspect of full-line wholesaling." He added that the crucial challenge for the wholesalers at this time "is to make our message heard."

Wholesalers should, he argued, seek out other services to capitalize on the outsourcing trends of European governments and drugmakers. However, in doing so, the temptation is to deny the sector's full-line wholesaling heritage and fail to communicate that service's value to all elements of the health care value chain.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight